titanocene dichloride

01/01/1999 - "Titanocene dichloride was again significantly active in the KTCTL-1M carcinoma xenograft and caused relative growth reductions by 50-65%. "
01/01/1998 - "Titanocene dichloride could be an active chemotherapeutic drug in women with ovarian carcinoma not responding to standard therapies."
01/01/1989 - "In 10 of these 14 carcinomas, titanocene dichloride effected growth suppression of greater than 50% in comparison with control tumors. "
09/01/1994 - "In the present study, the cytotoxic activity of titanocenedichloride in fourteen primary and twelve recurrent ovarian carcinomas (OvCA) was evaluated by an in vitro adenosine triphosphate (ATP) bioluminescence assay. "
06/01/1998 - "We have examined the in vitro activity of titanocene dichloride in two pairs of platinum-sensitive and resistant human ovarian carcinoma cell lines, A2780/2780CP and CH1/CH1cisR, and in mutated p53- and bcl-2-transfected clones of A2780 cells. "

11/01/1998 - "Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors."
08/01/1998 - "Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer."
11/01/2010 - "The titanocene dichloride released has obvious inhibition effect against lung tumor cells. "
12/01/2005 - "Titanocene dichloride exhibits anti-proliferative activity in a wide spectrum of murine and human tumors. "
03/01/2001 - "Enhanced anti-cancer activities of some derivatives of titanocene dichloride."

01/01/1998 - "Titanocene dichloride in the dosage of 3 x 30 mg/kg and 3 x 20 mg/kg brought about a significant reduction in tumour volume (p < 0.05) compared to the control group and to the treatment group under medication with titanocene dichloride 1 x 30 mg/kg. There were no significant changes in the body weight of nude mice. "
01/01/1998 - "The aim was to compare the effects of different dosages of titanocene dichloride on the growth of human tumour xenografts and nude mice body weight. "
01/01/1998 - "A statistically significant decrease (p<0.05) in body weight of the experimental animals was shown in groups treated with paclitaxel (alpha = -0.6878) and titanocene dichloride 3x40 mg/kg (alpha = -0.7194) compared to the control group which was treated with 0.9% saline (alpha = -0.2643). "
07/01/1998 - "Both a statistically significant decrease (p<0.05) in the body weight of the experimental animals (cisplatin: alpha = -0.5163, vinorelbine: alpha = -0.6598, paclitaxel: alpha = -0.6746, titanocene dichloride 3 x 30 mg/kg: alpha = -0.6259, titanocene dichloride 3 x 40 mg/kg: alpha = -0.7758) and a significant reduction (p<0.05) of the increase in tumor volume (cisplatin: beta = 12.049, vinorelbine: beta = 0.504, paclitaxel: beta = -1.636, titanocene dichloride 3 x 30 mg/kg: beta = 6.212, titanocene dichloride 3 x 40 mg/kg: beta= -0.685) was shown in all treated groups compared to the control group (alpha = -0.1398; beta = 23.056). "

01/01/1998 - "Phase II trial of titanocene dichloride in advanced renal-cell carcinoma."
01/01/1999 - "Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma."
01/01/1998 - "A total of 14 patients with metastatic renal-cell carcinoma (RCC) received 270 mg/m2 titanocene dichloride every 3 weeks for 6 weeks. "
01/01/1999 - "These results confirm a significant and remarkable antitumor activity of titanocene dichloride in three out of four human renal tumors xenografted to athymic mice and suggest that clinical studies of phase II with titanocene dichloride towards renal-cell carcinoma in human patients should be done in the near future."
07/01/1994 - "In vitro activity of titanocenedichloride in human renal cell carcinoma compared to conventional antineoplastic agents."

01/01/1984 - "Immunologic response to the treatment of Ehrlich ascites tumor with titanocene dichloride."
01/01/1984 - "After treatment of mice bearing Ehrlich ascites tumor (EAT) with titanocene dichloride, it could be shown (a) that all cured animals were able to reject EAT cells implanted subsequently and (b) that in the serum of these animals the contents of gamma-globulins was markedly increased, whereas after treatment with cis-platinum both the ability to reject EAT cells and the increase of gamma-globulins were less pronounced. "
06/01/1983 - "The intracellular distribution patterns of the metal atoms titanium and vanadium after in vivo as well as in vitro treatment of Ehrlich ascites tumor with the antitumor agents titanocene dichloride (TDC) or vanadocene dichloride (VDC) have been investigated by use of electron energy loss spectroscopy (EELS). "
01/01/1981 - "The in vitro growth-inhibiting potencies of titanocene dichloride (TDC), zirconocene dichloride (ZDC), hafnocene dichloride (HDC), vanadocene dichloride (VDC), and molybdocene dichloride (MDC) against Ehrlich ascites tumor (EAT) cells cultured in viro as permanently growing suspension cultures were determined. "